Although over 150 unique mutations affecting the coding sequence of CHM have been identified in patients with the X-linked chorioretinal disease choroideremia (CHM), no regulatory mutations have been reported, and indeed the promoter has not been defined. Here, we describe two independent families affected by CHM bearing a mutation outside the gene's coding region at position c.-98: C>A and C>T, which segregated with the disease. The male proband of family 1 was found to lack CHM mRNA and its gene product Rab escort protein 1, whereas whole-genome sequencing of an affected male in family 2 excluded the involvement of any other known retinal genes. Both mutations abrogated luciferase activity when inserted into a reporter construct, and by further employing the luciferase reporter system to assay sequences 5 ′ to the gene, we identified the CHM promoter as the region encompassing nucleotides c.-119 to c.-76. These findings suggest that the CHM promoter region should be examined in patients with CHM who lack coding sequence mutations, and reveals, for the first time, features of the gene's regulation.
attachment of a lipid moiety. The lipid modification, known as prenylation, of target Rab proteins is essential for intracellular vesicular transport (Seabra, Brown, & Goldstein, 1993; Seabra, Brown, Slaughter, Sudhof, & Goldstein, 1992) . A homologue, REP-2, encoded by CHML or CHM-like, functions similarly and appears to compensate for the absence of REP-1 in all tissues except the eye (Cremers, Armstrong, Seabra, Brown, & Goldstein, 1994) . CHM spans over 150 kb of Xq21.2 and contains 15 exons (van Bokhoven et al., 1994) . accessed February 2017) (Fokkema et al., 2011) . The mutation spectrum includes transitions and transversions leading to protein truncation, splice defects, indels, and large deletions ranging from a single exon to the full gene. Missense mutations predicted to alter protein structure or impair function (Esposito et al., 2011; Sergeev et al., 2009 ), transposon insertions (van den Hurk et al., 2003 , partial gene duplications (Chi, MacDonald, & Hume, 2013; Simunovic et al., 2016) , and other variations are infrequently found, but taken collectively, almost all known pathogenic variants in the CHM gene have been loss-of-function mutations that abolish functional REP-1 (McTaggart et al., 2002; Simunovic et al., 2016) . Notably, there is no apparent correlation between genotype and phenotype, with the age at onset of symptoms, visual acuity, and visual fields being unrelated to mutation type (Freund, Sergeev, & MacDonald, 2016; Simunovic et al., 2016) .
The promoter driving the expression of CHM has been heretofore unidentified. Analyses of promoter mutations causing inherited diseases can be useful in identifying transcription factors (TFs) involved in the regulation and expression of a gene of interest, as the activity of RNA polymerase II is mediated by the recruitment of general and sequence-specific transcription factors to cis-acting regulatory sequences. The core promoter directing basal level transcription is generally found between nucleotides −40 and +50 of the transcription start site (TSS) (de Vooght, van Wijk, & van Solinge, 2009 ), whereas proximal promoter elements typically reside within 1 kilo bases (kb), with additional enhancers, repressors, insulators acting even over distances of mega bases (Maston, Evans, & Green, 2006) . The investigation of regulatory elements in the context of human disease is complicated by the fact that in contrast to loss-of-function mutations, regulatory defects may produce small quantitative changes that are difficult to detect. Mutations in cis-acting regulatory sequences are a significant cause of human disease, and according to statistics compiled by the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk; accessed May 2016) approximately 2% of disease-causing point mutations are in noncoding regions of the genome (Stenson et al., 2014) . Though promoter defects can cause functionally important consequences for gene expression, their analysis is often not a regular part of DNA diagnostics as the investigation can be complex, laborious, and difficult to perform.
In this study, we report the first known regulatory mutations causing CHM. The absence of a genetic defect in a CHM family prompted us to explore the upstream noncoding region, revealing the novel promoter variant c.-98C>A. Subsequently, whole-genome sequencing (WGS) in an unrelated family with CHM identified a second variant of the same residue, c.-98C>T. We demonstrate the mutations' effects on transcription using a luciferase assay, and employ the same system to further characterize the boundary of the CHM promoter that spans the location. The results suggest a disruption of a transcription factor-binding site and impaired transactivation of the CHM promoter by the factor(s). Together, these studies further our understanding of regulation and expression of CHM and present a possible explanation for cases of unexplained CHM where no causative mutation is found within the gene.
MATERIALS AND METHODS

Clinical examination and study subjects
This study was approved by the institutions' respective ethics review boards. All procedures adhered to the tenets of the Declaration of Helsinki. Before participation, the purpose and risks of the study were explained, and informed consent was obtained. Blood samples were drawn, and a detailed pedigree and history was recorded.
We studied four males affected by CHM and one carrier female from two unrelated families. Individuals were examined by fundoscopy and functional ophthalmologic methods including some or all of: visual acuity testing, central visual fields, full-field electroretinography (ERG), optical coherence tomography (OCT), and fundus autofluorescence imaging. CHM was diagnosed by senior clinicians with expertise in inherited retinal disease based on clinical findings alone.
Affected males had a history of night vision loss and fundus appearance of peripheral retinopathy with broad areas of RPE and choroidal atrophy.
CHM Sanger sequencing
DNA was extracted from lymphocytes using conventional methodologies. Proband 5116 from family 1 (C127) was initially screened for CHM mutations in the coding sequence and splice sites by direct Sanger sequencing from PCR amplicons (Furgoch, Mewes-Arès, Radziwon, & MacDonald, 2014) . Additionally, 1 kb of the 5 ′ -flanking sequence was amplified with primers 5 ′ -CAGGGAAGGCCCACTACTGC -3 ′ and 5 ′ -CTTGTGGAAATGAGATCAAGTTAGG-3 ′ and sequenced with the same primers. With the exception of patient 111 and his parents, of family 2 (GC406) who underwent WGS, the remaining study individuals were genotyped only at position c.-98 to confirm the presence or absence of the respective variant. Annotation is in accordance with GenBank: NM_000390.3, where +1 represents the start of translation.
Cell culture
Leukocytes from patient 5116 were separated with Ficoll-Histopaque (Sigma-Aldrich, St. Louis, MO) from 10 ml of whole human blood collected in acid citrate dextrose tubes (BD, Franklin Lakes, NJ). A lymphoblastoid cell line was established by Epstein-Barr virus transformation within 48 hr of collection (Anderson & Gusella, 1984) . Cells were maintained in RPMI-1640 supplemented with 15% fetal calf serum and penicillin-streptomycin.
mRNA and protein analysis
Total RNA was extracted from 5×10 6 lymphoblastoid cells from patient 5116 and a healthy control, with the NucleoSpin RNA isolation kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's protocol. cDNA was transcribed from 5 g of total RNA with the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, IL) using a random hexamer primer mix. PCR amplification from cDNA with forward primer 5 ′ -TAATAGTCACATGACACGTTTCCCG-3 ′ , paired with 5 ′ -TGGATTCAGGCAAACCCGT-3 ′ , or 5 ′ -TTTAAAATGAGCAAGTCAATGTGC-3 ′ as a reverse primer was used to detect partial transcript (spanning the junction of exon 1 and 2), or the entire coding sequence of CHM encompassed by 15 exons, respectively. GAPDH was also amplified as a positive control with intron-spanning primers.
Protein was extracted from 2×10 6 lymphoblastoid cells and immunoblot analysis of REP-1 was performed as previously described (Furgoch et al., 2014) .
WGS
UK proband 111 (GC406) and his unaffected parents 190 and 192 underwent WGS as part of the 100000 Genomes Project.
Briefly, genomic DNA was processed using the Illumina TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc., San Diego, CA, USA) and sequenced using an Illumina HiSeq X Ten, generating minimum coverage of 15× for >97% of the callable autosomal genome. Reads were aligned to build GRCh37 of the human genome using the Isaac aligner (Illumina Inc.). SNVs and indels were identified using Platypus v0.8.1 and annotated using Cellbase (https://github.com/opencb/cellbase). Variant filtering was performed using minor allele frequency (MAF) in publicly available and in-house datasets, predicted protein impact, and familial segregation. Surviving variants were prioritized using a prespecified virtual gene panel from Figure 1A . All constructs generated
were Sanger sequenced to ensure fidelity. Primer sequences for the generation of plasmid inserts are available upon request.
Luciferase assay
HEK293T 
Statistical analysis
All data were expressed as mean ± SD. Data from the luciferase assay represent two independent experiments with triplicate measurements. Differences between groups were examined for statistical significance using Student's t-test. A P value < 0.01 denoted the presence of a statistically significant difference.
RESULTS
Clinical characterization of CHM
Family 1
We investigated a progressive retinal degeneration in a Caucasian family of American origin (C127). Remarkably, the proband 5116 was the
The constructs portrayed on the left were inserted upstream of the luciferase gene in pGL3-basic. Nucleotide +1 represents the translation start site. The promoterless pGL3-basic served as a negative control. B: The mutations c.-98C>A and c.-98C>T abolish transcription, whereas the minimal construct c.-119_-76 is sufficient for robust expression of the reporter gene not significantly different from even that of the nearly 4-kb construct. All constructs were transiently transfected into HEK293T cells. A dual-luciferase reporter assay was used to assess the potential promoter activity of various sized inserts and the c.-98 mutants. Promoter activity is shown as a ratio of firefly luciferase over Renilla luciferase present on the transfection control plasmid pRL-CMV to account for interwell variation. Activity is normalized to that of the reference construct pGL3-1093_-31 that is artificially set to equal 100. Activity significantly different (P < 0.01) from the reference construct is denoted by an asterisk. Error bars represent ± 1SD offspring of a consanguineous union between second cousins, with an affected father, and a carrier mother. To our knowledge, this has never been reported with CHM, and it necessitated a thorough and accurate diagnosis of X-linked CHM and exclusion of an autosomal-recessive, or even an unusual male-male transmission as cause for the disease. An investigation of the extended family for which the pedigree is reported in Figure 2A , however, clearly demonstrated the X-linked inheritance of the disease.
Patient 5116 was initially seen at the age of 56 years, when he was referred by a retinal specialist with a diagnosis of CHM. At his most recent examination, aged 76 years, best corrected visual acuity (BCVA) was measured as 6/19 OD and 6/15 OS. Visual fields were reduced to less than 5°. The full-field ERG showed nondetectable darkadapted rod-driven responses as well as nondetectable cone responses to a 30-Hz flicker stimulus. OCT imaging indicated loss of the photoreceptor layer across the periphery of the fundus with only a small island of RPE remaining in the macula. Posterior segment examination showed a hypo-pigmented fundus with significant atrophy of the RPE and choroid with areas of bare sclera (Fig. 3) . These findings are consistent with an advanced state of CHM.
The proband's daughter 5113 was examined at 33 years of age and did not report any vision difficulties. When examined, BCVA was 6/6, both eyes. Full-field ERG testing of the left eye showed that darkadapted rod-driven responses were reduced by 50% in amplitude (42.5 V) and a normal b-wave implicit time (81.6 msec). Light-adapted cone-driven responses to a 30-Hz flicker stimulus were reduced by 50% in amplitude (27.6 V) and borderline reduced in implicit time (25.6 msec). These findings were consistent with a classic carrier state of CHM.
The proband's father and one brother 5149 were reported to have been previously diagnosed with CHM, whereas a second brother 5147 was reported to be unaffected. Findings are summarized in Table 1 .
Family 2
Family 2 (GC406) was a Caucasian family of British origin with a history of CHM. Proband 111 was first examined at the age of 13 years, displaying a reduced, but not delayed, full-field ERG with flicker and bright flash responses both within normal limits. He remained asymptomatic until the age of 32 years. Confrontational visual field testing at the age of 35 years showed bilateral infratemporal scotoma, and BCVA was 6/5 in both eyes. He is considered symptomatically mild with retained central macular structure.
Of his two maternal uncles, 151 was diagnosed at the age of 12 years. Fundus abnormalities typical of CHM were noted. 161 was diagnosed at the age of 8 years, and upon examination at the age of 37 years exhibited moderately constricted visual fields particularly in the superior field bilaterally. BCVA was reduced to count fingers' vision OD and 6/36 OS. Fundus examination was consistent with a clinical diagnosis of CHM. The pedigree is reported in Figure 2B , and clinical findings summarized in Table 1 . (Sherry et al., 2001) . The proband's affected brother (5149) was also found to harbor the variant, whereas it was absent in the unaffected brother (5147) available for testing. The obligate carrier status was confirmed in the proband's daughter (5113). The location of the variant strongly suggested a regulatory mutation, as evaluation of entries in the HGMD reveals that most promoter mutations are located between +50 and −500 from the TSS of a gene (Stenson et al., 2014) .
Prior genetic analysis of the coding exons of the CHM gene did not 
Molecular diagnosis of CHM in 5116
Immunoblot analysis of protein harvested from a cell line derived and c.-98C>T, we observed complete abrogation of promoter activity (Fig. 1B) in the mutants. The drop from 100 ± 9.5 to 2.0 ± 0.3 and 1.3 ± 0.4, respectively, as measured in normalized RLUs ± 1 standard deviation is even significantly lower than that of the negative control pGL3-basic that does not contain a promoter sequence, reading at 5.8 ± 0.9.
This startling observation strongly suggested that the mutation spans an element essential to promoter activity. 
Characterization of CHM promoter
To further characterize the promoter, we proceeded to assay progressively shorter constructs, deleting sequences from the −5 ′ and −3 ′ of the 1-kb construct to define its boundaries (Fig. 1A) . Working from the 5 ′ end, the approximately 400, 300, and 100 bp constructs, pGL3-437_-31, pGL3-346_-31, and pGL3-119_-31, did not significantly differ from the 1-kb containing reference plasmid pGL3-1093_-31, reading at 100.2 ± 11.4, 96.1 ± 10.6, and 97.7 ± 8.1 RLUs, respectively. Yet, upon deleting a further 11 bp, we observed a significant drop to 39.8 ± 7.6 RLU with pGL3-108_-31. Having delineated the −5 ′ boundary of the promoter as extending to no further than nucleotide c. We therefore conclude that the two mutations at residue c.-98 impair CHM transcription enough to result in CHM. For the several gene therapy trials currently underway employing a gene replacement strategy (Dimopoulos, Chan, MacLaren, & MacDonald, 2015) , individuals bearing these genotypes would be suitable candidates. The two variants have been submitted and published in the LOVD Retinal and Hearing Impairment Genetic Mutation Database (Fokkema et al., 2011) .
Having identified mutations that evidently abolished transcription, we interpreted their location to span a region crucial for gene expression, and set out to define the boundaries of the gene's promoter. Surprisingly, after analyzing fragments as long as 4 kb, we found a short 44 bp DNA fragment to be wholly responsible for driving expression.
The region c.-119 to c.-76 comprises the entirety of the CHM proximal promoter, and is able to drive robust transcription in an in vitro luciferase assay. The region implicated amounts to less than 3% of the length of the CHM coding sequence where the large majority of reported causative mutations have been found (Fokkema et al., 2011) .
A recent investigation of a large disease cohort (74) found causative mutations in the gene in 94% of the cases previously diagnosed with CHM (Simunovic et al., 2016) . The remaining 6% can be understood to be comprising regulatory mutations, incorrect diagnoses, or deep intronic variant causing cryptic splicing (Carss et al., 2017) . Promoter defects are therefore expected to be responsible for a small minority of CHM cases. The identified region, however, becomes an obvious area for examination in patients in whom no coding sequence mutation is found.
A promoter or regulatory mutation can be expected to either increase or decrease transcriptional activity mediated by the altered binding capacity of transacting protein factors specific to a DNA sequence in the promoter region. In this case, the interaction appears to be entirely disrupted based on the null expression of a reporter driven by mutated sequence in our luciferase assay. Impaired transcription due to a 1-bp mutation in a promoter region is unusual, but has been reported previously as in the case of single-base mutations stimulating additional transcriptional activity at the OVOL2 promoter causing autosomal-dominant corneal endothelial dystrophies (Davidson et al., 2016) . On the other hand, decreased transactivation of NMNAT1 due to a single-nucleotide change in the promoter was found to cause Leber congenital amaurosis (Coppieters et al., 2015) . (Myslinski, Krol, & Carbon, 1998; Schaub, Myslinski, Schuster, Krol, & Carbon, 1997) and was initially connected with the binding motif TTCCCATTATGCACCGCG (SBS1) (Myslinski, Gerard, Krol, & Carbon, 2006) . Genome-wide studies revealed the binding site for the factor to be frequently found with an adjacent 5 ′ accessory sequence, forming the ACTACAATTCCCATTATGCACCGCG (SBS2) motif. SBS2 comprises both a THAP domain-containing protein 11 (THAP11) and ZNF143-binding site, with the factors believed to act in a competitive manner (Ngondo-Mbongo, Myslinski, Aster, & Carbon, 2013) . The recruitment of THAP11 to its canonical binding site ACTAYRNNNCCCR is most frequently associated with upregulation genes essential to protein biosynthesis and energy production (Dejosez et al., 2010) . More recently, ZNF143 was suggested to cooperatively occupy SBS2 sites with THAP11 and a third factor, the scaffold protein host cell factor 1 (HCFC1) in vivo (Vinckevicius, Parker, & Chakravarti, 2015) . (Blanchette et al., 2004; Kuhn et al., 2007) . Representatives of birds and amphibian classes, however, lack homology in the region, whereas in fish a corresponding region is absent altogether. The promoter, therefore, cannot be considered an ultraconserved noncoding element (Dimitrieva & Bucher, 2013) . Several alignments are listed in Table 2 .
Studies of CHM mRNA and protein localization have found a broad expression profile for both. In mice, evidence of transcription was found in multiple cell types and in every major layer of retina (Keiser, Tang, Wei, & Bennett, 2005) , whereas immunolabeling of primate retina showed REP-1 localized to both rod and cones (Dimopoulos et al., 2015) . Studies in human and primate retina found that mRNA levels did not correspond to the pattern of disease expression; little CHM was detected in the RPE and choroid, and there were no marked regional differences in the concentration of CHM mRNA apparent with foveal versus mid-peripheral total RNA despite affected males typically exhibiting a preservation of central vision until late in the disease (Bernstein & Wong, 1998) . Additionally, REP-1 can be readily detected in human fibroblasts or peripheral blood mononuclear cells (Furgoch et al., 2014; MacDonald, Mah, Ho, Lewis, & Seabra, 1998) .
Taken together with ZNF143's characterization as one of the most common and ubiquitously expressed TFs (Myslinski et al., 1998) , a picture emerges of widespread and nonspecific transcription of CHM, despite CHM's manifestation as an ocular disease. Indeed, patients' apparent lack of systemic symptoms can be understood to result not from tissue-specific expression of REP-1, but from the differing affinities of REP-1 and REP-2 for target Rabs, which may themselves be differentially expressed or possess tissue-or cell-specific activity. Investigators have implicated Rab27 (Seabra, Ho, & Anant, 1995) and Rab38 (Kohnke et al., 2013) as possible contributors.
The study presented here also poses interesting questions, such as whether mutations of other residues less critical to transactivator binding in the CHM promoter that diminish, but not completely abolish mRNA expression, can result in a milder phenotype, or a different rate of progression of CHM. Currently, the dbSNP database lists no known SNPs between c.-119 to c.-76 (Sherry et al., 2001) . Having shown the CHM region responsible for the regulation of its expression, described for the first time the features of its promoter, and extended the inventory of molecular changes causing CHM, the findings are of clinical and diagnostic interest and present an obvious area of examination for patients with CHM in whom no coding sequence mutation has been found. Furthermore, elucidating the roles of ZNF143, THAP11, tcca--cccaa-gaactacaa-cac cagaatgcact-g-----tttt-ctt--ttc
Pan troglodytes (chimp) tcca--cccaa-gaactacaa-cac cagaatgcact-g-----tttt-cct--ttc
Pongo abelii (orangutan) ttccatcccaa-gaactacaa-cac cagaatgcatt-g-----tttttcct--ttc
Callithrix jacchus (marmoset) tcca--cccaa-gaactacaa-cac cagaatgcatt-g-----tttt-cct--ttc
Mus musculus (mouse) gcgt--ctcta-gaactacaa-cac cagaatgcact-g-----tttt-tcc--ttc
Rattus norvegicus (rat) gcta--cccta-aaactacaa-cac cagaatgcact-g-----tttt-tcc--ttc
Equus caballus (horse) gcca--cccaa-gaactacaa-tac cagaatgcact-g-----tttt-ccc--ttc
Canis familiaris (dog) gcca--cccac-gaactacaa-tat cagaatgcatt-g-----tttt-tcc--ttc
Pteropus vampyrus (megabat) gcca--cccaa-ggactacaa-tac cagaatgcact---------tt-tcc----c
Dasypus novemcinctus (armadillo) tcaa--cca-atgaactacaa-tac cagaatgcact-a-----tttt-cct--ttc
Monodelphis domestica (opossum) tcct--gccac-gaactacaa-atc cagaatgcatt-g-----cgct-ccc----g
Anolis carolinensis (lizard) ------------a-gaactacag-caa cacaatgcact-gcaatatggt-cac--atc
Gallus gallus (chicken) =========================================================
Xenopus tropicalis (X. tropicalis) =========================================================
Dani rerio (zebrafish)
HCFC1, or other distal factors will prove an important step toward understanding the complete picture of CHM's regulation.
